scispace - formally typeset
P

Peter Kenemans

Researcher at VU University Medical Center

Publications -  228
Citations -  12639

Peter Kenemans is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 59, co-authored 228 publications receiving 12293 citations. Previous affiliations of Peter Kenemans include Loyola University Chicago & Netherlands Cancer Institute.

Papers
More filters
Journal ArticleDOI

Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer

TL;DR: The Fallopian tubes of women predisposed to developing ovarian cancer frequently harbour dysplastic changes, accompanied by changes in cell‐cycle and apoptosis‐related proteins, indicating an increased risk of developing tubal cancer.
Journal ArticleDOI

Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study

TL;DR: Persistent infection with high-risk human papillomavirus is necessary for development and maintenance of cervical intraepithelial neoplasia CIN 3, and all women with severe dyskaryosis should be referred to gynaecologists, whereas women with mild to moderate dysKaryosis ought to be referred only after a second positive test for high- risk human papillsomav virus at 6 months.
Journal ArticleDOI

The Effects of Tibolone in Older Postmenopausal Women

TL;DR: Tibolone reduced the risk of fracture and breast cancer and possibly colon cancer but increased therisk of stroke in older women with osteoporosis and the study was stopped at the recommendation of the data and safety monitoring board.
Journal ArticleDOI

The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease : natural history up to 36 months

TL;DR: The results show that the continuous presence of high‐risk HPV types in women with cytomorphologically abnormal smears is a strong marker for progressive CIN disease.
Journal ArticleDOI

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.

TL;DR: This work identified peptides of (mutant) p53 capable of binding to HLA‐A2.1 in an in vitro assay and obtained CD8+ cytotoxic T lymphocyte clones capable of specifically lysing target cells loaded with wild‐type or tumor‐specific mutant p53 peptides.